S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
NASDAQ:CRVS

Corvus Pharmaceuticals News Headlines

$2.02
-0.23 (-10.22%)
(As of 01/18/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.01
$2.25
50-Day Range
$2.02
$4.64
52-Week Range
$1.86
$9.54
Volume
434,009 shs
Average Volume
450,537 shs
Market Capitalization
$94.03 million
P/E Ratio
33.67
Dividend Yield
N/A
Beta
0.88
Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Corvus Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRVS
News Sentiment

0.38

0.33

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRVS Articles
This Week

5

1

CRVS Articles
Average Week



Corvus Pharmaceuticals (NASDAQ:CRVS) News Headlines Today

SourceHeadline
seekingalpha.com logoCorvus Pharma initiates Phase 1/1b trial of CPI-818 for T-cell lymphomas in China
seekingalpha.com - January 14 at 3:06 PM
finance.yahoo.com logoCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
finance.yahoo.com - January 13 at 9:06 PM
finance.yahoo.com logoInsiders who bought stock earlier this year lose -US$118k as Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) drops to US$112m
finance.yahoo.com - January 1 at 9:55 AM
finance.yahoo.com logoNew Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation
finance.yahoo.com - December 13 at 1:55 PM
finance.yahoo.com logoCorvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
finance.yahoo.com - November 12 at 8:30 AM
finance.yahoo.com logoCorvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
finance.yahoo.com - November 10 at 6:33 PM
finance.yahoo.com logoCorvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
finance.yahoo.com - November 2 at 8:18 PM
finance.yahoo.com logo2 Biotech Stocks That Surged More Than 100% in September
finance.yahoo.com - October 6 at 12:14 PM
nasdaq.com logoCorvus Pharmaceuticals Inc Shares Close the Day 23.4% Lower - Daily Wrap
nasdaq.com - October 1 at 3:32 AM
finance.yahoo.com logo4 Buy-Ranked Stocks that Soared Over 20% in the Past Week
finance.yahoo.com - September 29 at 12:06 AM
stocknews.com logoIs Corvus Pharmaceuticals a Good Healthcare Stock to Add to Your Portfolio?
stocknews.com - September 27 at 9:35 AM
finance.yahoo.com logoWhy Corvus Pharmaceuticals Stock Is Down Today
finance.yahoo.com - September 22 at 6:37 PM
baystreet.ca logoCorvus Flat on Drug Trial News
baystreet.ca - September 22 at 1:37 PM
finance.yahoo.com logoCorvus Posts Data From Discontinued Mupadolimab COVID-19 Program
finance.yahoo.com - September 22 at 1:37 PM
finance.yahoo.com logoCorvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease
finance.yahoo.com - September 22 at 7:51 AM
nasdaq.com logoWe Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Easily Afford To Drive Business Growth
nasdaq.com - September 20 at 1:44 PM
finance.yahoo.com logoImplied Volatility Surging for Corvus Pharmaceuticals (CRVS) Stock Options
finance.yahoo.com - September 20 at 1:44 PM
benzinga.com logoWhat's Going On With Corvus Pharmaceuticals Stock Today?
benzinga.com - September 17 at 12:46 PM
finance.yahoo.com logoBeiGene (BGNE) Scores Third FDA Nod for Brukinsa in Lymphoma
finance.yahoo.com - September 16 at 3:52 PM
finance.yahoo.com logoDo Institutions Own Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares?
finance.yahoo.com - September 3 at 11:48 AM
finance.yahoo.com logoBeiGene (BGNE) Gets FDA Nod for Brukinsa Label Expansion
finance.yahoo.com - September 2 at 3:21 PM
markets.businessinsider.com logoAngel Pharmaceuticals Announces IND Acceptance for Clinical Trial of ITK Inhibitor CPI-818 in China
markets.businessinsider.com - August 16 at 9:49 PM
finance.yahoo.com logoCorvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China
finance.yahoo.com - August 16 at 9:49 PM
bizjournals.com logoHow a Bay Area biotech uncovered a potential Covid fighter — and why it later dumped it
bizjournals.com - August 11 at 8:12 PM
finance.yahoo.com logoDown 23.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corvus (CRVS)
finance.yahoo.com - August 5 at 2:17 PM
finance.yahoo.com logoCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
finance.yahoo.com - August 2 at 5:41 PM
finance.yahoo.com logoCorvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
finance.yahoo.com - August 2 at 5:41 PM
finance.yahoo.com logoDown 15.8% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
finance.yahoo.com - July 20 at 2:12 PM
seekingalpha.com logoCorvus shares drop after scrapping late-stage mupadolimab COVID-19 trial
seekingalpha.com - July 16 at 10:50 PM
benzinga.com logoThe Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
benzinga.com - July 16 at 12:49 PM
finance.yahoo.com logoCorvus Pulls Plug On Mupadolimab COVID-19 Program With Candidate Now Prioritized In Oncology
finance.yahoo.com - July 16 at 12:49 PM
finance.yahoo.com logoCorvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations
finance.yahoo.com - July 15 at 8:06 PM
nasdaq.com logoHere's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like
nasdaq.com - July 7 at 10:00 AM
finance.yahoo.com logoCorvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 25 at 7:51 PM
finance.yahoo.com logoThe Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 2.8% More Shares
finance.yahoo.com - May 8 at 12:51 PM
markets.businessinsider.com logoCorvus Pharma - In The Race To Fight Viral Variants
markets.businessinsider.com - May 6 at 2:43 PM
finance.yahoo.com logoCorvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program
finance.yahoo.com - May 5 at 10:57 AM
finance.yahoo.com logoCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
finance.yahoo.com - April 29 at 8:32 PM
finance.yahoo.com logoIs Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - April 20 at 10:10 AM
finance.yahoo.com logoCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 25 at 12:30 PM
finance.yahoo.com logoCorvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences
finance.yahoo.com - March 5 at 8:47 AM
finance.yahoo.com logoCo-Founder Richard Miller Just Bought 8.5% More Shares In Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
finance.yahoo.com - February 19 at 7:47 AM
finance.yahoo.com logoCorvus Pharmaceuticals Announces Closing of Public Offering of Common Stock
finance.yahoo.com - February 17 at 6:15 PM
finance.yahoo.com logoCorvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - February 12 at 9:48 AM
finance.yahoo.com logoCorvus Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 11 at 6:30 PM
msn.com logoTop Analyst Upgrades and Downgrades: Akamai, Avaya, Canopy Growth, Corsair Gaming, Playtika, Virgin Galactic and More
msn.com - February 10 at 9:33 AM
finance.yahoo.com logoCorvus Initiates CPI-006 Pivotal Trial In COVID-19 Patients; Results Expected by 2021 End
finance.yahoo.com - February 4 at 3:16 PM
finance.yahoo.com logoCorvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19
finance.yahoo.com - February 4 at 10:15 AM
finance.yahoo.com logoWhat Type Of Shareholders Make Up Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Share Registry?
finance.yahoo.com - January 30 at 9:28 AM
finance.yahoo.com logoIs CRVS A Good Stock To Buy Now?
finance.yahoo.com - December 7 at 5:34 PM
Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.